EGFR and glioblastoma: Combination ABT-414 and TMZ treatment compared with TMZ/lomustine monotherapy increased median PFS and overall survival (OS), warranting the investigation of ABT-414 in combination with standard chemo-irradiation and TMZ in phase III trials for newly diagnosed EGFR-amplified GBM patients (NCT02573324).